Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers

A method of treating a subject having a solid tumor comprising:

• administering to the subject an effective amount of an oncolytic virus expressing a truncated CD19 (OV19t), the nucleotide sequence of the OV19t comprising:
• (a) a nucleotide sequence that is at least 99% identical to nucleotides 5,014-178,073 of SEQ ID NO:
• 1 over the entire length of nucleotides 5,014-178,073 of SEQ ID NO:
• 1;
• and
• (b) encodes a truncated human CD19 (CD19t) comprising the amino acid sequence of SEQ ID NO:4;
• and
• administering to the subject an effective amount of a bispecific T cell engager (TCE) that binds to CD19t and comprises:
• (i) a CD19-targeted scFv comprising a variable heavy (VH) chain selected from SEQ ID NOs:
• 73, 81, and 89 and a variable light (VL) chain selected from SEQ ID NOs:
• 69, 77, and 85;
• and
• (ii) a CD3-targeted scFv comprising a VH selected from SEQ ID NOs:
• 97, 113, 122, 103, and a VH comprising complementarity determining regions 1-3 (CDR1-CDR3) comprising SEQ ID NOs:
• 102-104, respectively, and a VL selected from SEQ ID NOs:
• 93, 109, 118, 126, and a VL comprising CDR1-CDR3 comprising SEQ ID NOs:
• 98-100, respectively.